Uroxatral
NDC Package 54868-5046-2
Package Information
Uroxatral is alfuzosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). Marketed by Physicians Total Care, Inc., this product is identified by NDC 54868-5046 and is authorized under FDA application NDA021287.
Identification & Billing
- RxCUI: 861132 - alfuzosin HCl 10 MG 24HR Extended Release Oral Tablet
- RxCUI: 861132 - 24 HR alfuzosin hydrochloride 10 MG Extended Release Oral Tablet
- RxCUI: 861132 - alfuzosin hydrochloride 10 MG 24 HR Extended Release Oral Tablet
- RxCUI: 861134 - Uroxatral 10 MG 24HR Extended Release Oral Tablet
- RxCUI: 861134 - 24 HR alfuzosin hydrochloride 10 MG Extended Release Oral Tablet [UroXatral]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 54868 - Physicians Total Care, Inc.
- 54868-5046 - Uroxatral
- 54868-5046-2 - 90 TABLET, EXTENDED RELEASE in 1 BOTTLE
- 54868-5046 - Uroxatral
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (54868-5046). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 54868-5046-2 identifies a specific commercial package of 90 tablet, extended release in 1 bottle of Uroxatral, labeled by Physicians Total Care, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 90 billable units per package. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Physicians Total Care, Inc. on June 22, 2004. The current certification is valid through December 31, 2017.
What are the primary indications for this medication?
Alfuzosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Alfuzosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.
How is this Physicians Total Care, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 54868504602. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.